NASDAQ
10.05USD
-0.07 (-0.69%)
We have scored 18 news catalysts on Alphatec Holdings, Inc. (ATEC) over the past 12 months. The biggest single-day move next to one of them came Feb 27, 2026, when ATEC closed −2.8%: “Alphatec Holdings: Buy On Solid Results And Outlook”. Coverage across the window leans negative (average ticker sentiment −0.32). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.5B
P/E
—
EPS
—
Beta
0.85
52W range
6.82-23.29
Day range
9.80–10.06
Open
10.03
Prev close
10.12
Volume
1.7M
Avg volume
2.5M
Dividend
0.00
IPO
2006-06-01
Analysts publish price targets on ATEC, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
6 analyst price targets from $11 to $16
as of 2026-09-24
The market is 28% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Alphatec Holdings, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ATEC: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Alphatec Holdings, Inc. is a medical technology firm dedicated to engineering and advancing solutions for the surgical management of spinal conditions. Its product array includes the Alpha InformatiX platform, notably the SafeOp Neural InformatiX System, which is engineered to reduce the likelihood of nerve injury during surgery. For access and positioning, Alphatec offers systems such as the Sigma transforaminal lumbar interbody fusion pedicle-based access system, the Sigma PTP Access and Patient Positioning System, and the Squadron lateral retractor, all designed to optimize surgical outcomes. The company's robust line of spinal fixation devices features the Invictus Spinal Fixation System, capable of addressing various thoracolumbar pathologies, alongside its minimally invasive SingleStep System and adaptable Modular Fixation Systems, which enhance screw modularity. Further fixation options include the OsseoScrew system for spinal column restoration and the comprehensive Arsenal spinal fixation platform, catering to a spectrum of degenerative to deformity procedures. Alphatec also provides anterior lumbar plating solutions like the Aspida Anterior Lumbar Plating System for interbody fusion and the AMP Anti-Migration Plate, in addition to cervical fixation options such as the OCT Spinal Fixation System, the Trestle Luxe Anterior Cervical Plate System, and the Insignia Anterior Cervical Plate System. Its portfolio extends to interbody implants, including IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Implants. A comprehensive suite of biologics is also available, featuring Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. The company additionally offers EOS imaging products. Alphatec Holdings markets its diverse product range throughout the United States via a network of independent distributors and its own direct sales force. Established in 1990, the company's headquarters are located in Carlsbad, California.
The price sits 28% below the median published target and below every single analyst model, meaning the market flatly rejects the bullish consensus and prices in a high probability of continued shortfalls.
What the disagreement turns on
Whether surgical unit volumes can actually accelerate to fulfill the growth the price requires, which can be directly tested via the available unit volume data.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
